EMA Authorised: Byannli (previously Paliperidone Janssen-Cilag International) (paliperidone palmitate) — Janssen-Cilag International N.V.

View source ↗

Summary

The EU authorised Byannli (paliperidone palmitate) for schizophrenia, as a long-acting injectable antipsychotic under Janssen-Cilag International N.V.; decision…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Byannli (paliperidone palmitate)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia. MAH: Janssen-Cilag International N.V.. Decision date: 19/07/2024